412 Shares in McKesson Co. (NYSE:MCK) Acquired by Aspiriant LLC

Aspiriant LLC purchased a new stake in shares of McKesson Co. (NYSE:MCK) during the fourth quarter, Holdings Channel.com reports. The firm purchased 412 shares of the company’s stock, valued at approximately $235,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Pure Financial Advisors LLC increased its position in shares of McKesson by 3.3% in the 4th quarter. Pure Financial Advisors LLC now owns 792 shares of the company’s stock valued at $452,000 after acquiring an additional 25 shares during the period. Koshinski Asset Management Inc. increased its holdings in shares of McKesson by 0.9% in the fourth quarter. Koshinski Asset Management Inc. now owns 2,404 shares of the company’s stock valued at $1,370,000 after purchasing an additional 22 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in shares of McKesson by 3.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 632 shares of the company’s stock worth $360,000 after purchasing an additional 22 shares during the last quarter. M.E. Allison & CO. Inc. acquired a new stake in shares of McKesson during the fourth quarter worth about $264,000. Finally, Successful Portfolios LLC purchased a new stake in McKesson in the fourth quarter valued at approximately $219,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Trading Down 1.2 %

MCK stock opened at $585.51 on Wednesday. The business’s 50-day moving average is $594.65 and its 200 day moving average is $561.08. McKesson Co. has a 12-month low of $464.42 and a 12-month high of $637.51. The stock has a market cap of $74.32 billion, a price-to-earnings ratio of 30.32, a PEG ratio of 1.28 and a beta of 0.52.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 EPS for the quarter, topping the consensus estimate of $6.88 by $0.19. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The firm had revenue of $93.65 billion during the quarter, compared to analysts’ expectations of $89.33 billion. During the same period in the previous year, the business earned $6.23 earnings per share. The firm’s revenue for the quarter was up 21.3% on a year-over-year basis. As a group, equities analysts forecast that McKesson Co. will post 32.73 EPS for the current fiscal year.

McKesson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 2nd. Investors of record on Monday, December 2nd were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $2.84 annualized dividend and a yield of 0.49%. McKesson’s dividend payout ratio is presently 14.71%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MCK. StockNews.com raised shares of McKesson from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. Robert W. Baird raised McKesson from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $531.00 to $688.00 in a research report on Thursday, November 7th. Baird R W upgraded McKesson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. Wells Fargo & Company lifted their price target on McKesson from $535.00 to $641.00 and gave the company an “equal weight” rating in a research report on Friday, December 13th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on McKesson from $623.00 to $579.00 and set a “buy” rating on the stock in a research report on Wednesday, September 25th. Two research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $646.14.

Insider Buying and Selling at McKesson

In other news, EVP Leann B. Smith sold 579 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total value of $331,645.41. Following the completion of the sale, the executive vice president now directly owns 864 shares in the company, valued at $494,890.56. This represents a 40.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.11% of the stock is owned by insiders.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.